How brain processes are rewired in Parkinson's disease

Published Date: 02 Mar 2023

Researchers from the University of Queensland have confirmed that genes associated with the risk of Parkinson's disease also contribute to the production of cellular debris in the brain.

Read Full News

Latest News

Phase 2 Study of Lenadogene Nolparvovec Gene Therapy for Leber Hereditary Optic Neuropathy: The REVISE Trial Isabella Ciccone, MPH

The REVISE trial, a phase 2 study evaluating GenSight Biologics’ lenadogene nolparvovec in patients with Leber hereditary optic neuropathy, is expected to begin in January 2026.

FDA Lifts Clinical Hold on Intellia’s Trial for Gene Editing Therapy Nex-Z in ATTRv-PN, Places Holds on REGENXBIO MPS Trials Noah Stansfield

Intellia’s trial for nex-z in ATTR-CM remains under clinical hold.

NeuroVoices: Kathrin LaFaver, MD, FAAN, DipABLM, on What’s Ahead for Movement Disorder Care in 2026 Kathrin LaFaver, MD, FAAN, DipABLM, Isabella Ciccone, MPH

The neurologist in the Department of Neurology at Saratoga Hospital Medical Group shared what excites her most about the future of neurology, specifically for movement disorders, in 2026.

Real-World Study Provides Support for Lamotrigine in Treating Non-Dystrophic Myotonias Louie Pasculli

Trial data showed that treatment with lamotrigine reduced myotonia severity in adults with genetically confirmed non-dystrophic myotonias, with sustained benefit and an acceptable safety profile.

Norwegian Registry Study Links Maternal Diabetes to Doubled Risk of Multiple Sclerosis in Offspring Marco Meglio

A recent study linked maternal diabetes to a doubled risk of multiple sclerosis in offspring, highlighting prenatal factors in MS susceptibility.

Priority Review Granted for Weekly Subcutaneous Lecanemab Dosing in Early Alzheimer Disease Isabella Ciccone, MPH

If approved, lecanemab-irmb would provide an at-home subcutaneous injection option for both treatment initiation and maintenance dosing for patients with early-stage Alzheimer disease.

Todays Updates

New 3-Year EMBARK Data Highlights Continued Therapeutic Effect of Gene Therapy Elevidys in Duchenne Marco Meglio

New findings from the EMBARK study highlight Elevidys' significant long-term benefits in slowing Duchenne muscular dystrophy progression in young patients.

Higher CTE Stages Linked to Increased Dementia Risk, Postmortem Analysis Shows Louie Pasculli

A study of 614 brain donors revealed that individuals with stage III or IV CTE face the greatest risk of dementia.

FDA Approves First Dual-Agent Eye Drop for Near Vision Loss

FDA Approves First Dual-Agent Eye Drop for Near Vision Loss

Todays Updates

New 3-Year EMBARK Data Highlights Continued Therapeutic Effect of Gene Therapy Elevidys in Duchenne Marco Meglio

New findings from the EMBARK study highlight Elevidys' significant long-term benefits in slowing Duchenne muscular dystrophy progression in young patients.

Higher CTE Stages Linked to Increased Dementia Risk, Postmortem Analysis Shows Louie Pasculli

A study of 614 brain donors revealed that individuals with stage III or IV CTE face the greatest risk of dementia.

FDA Approves First Dual-Agent Eye Drop for Near Vision Loss

FDA Approves First Dual-Agent Eye Drop for Near Vision Loss

Latest News

The REVISE trial, a phase 2 study evaluating GenSight Biologics’ lenadogene nolparvovec in patients with Leber hereditary optic neuropathy, is expected to begin in January 2026.

Intellia’s trial for nex-z in ATTR-CM remains under clinical hold.

The neurologist in the Department of Neurology at Saratoga Hospital Medical Group shared what excites her most about the future of neurology, specifically for movement disorders, in 2026.

Trial data showed that treatment with lamotrigine reduced myotonia severity in adults with genetically confirmed non-dystrophic myotonias, with sustained benefit and an acceptable safety profile.

A recent study linked maternal diabetes to a doubled risk of multiple sclerosis in offspring, highlighting prenatal factors in MS susceptibility.

If approved, lecanemab-irmb would provide an at-home subcutaneous injection option for both treatment initiation and maintenance dosing for patients with early-stage Alzheimer disease.

News All Time

Episode 159: Key Practice Takeaways From the New AAN Functional Seizure Guidelines Marco Meglio, Benjamin Tolchin, MD, MS, FAAN

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Benjamin Tolchin, MD, MS, FAAN. [LISTEN TIME: 23 minutes]

AskBio’s Late-Onset Pompe Disease Gene Therapy AB-1009 Cleared for Phase 1/2 Trial Noah Stansfield

AskBio noted that AB-1009 also recently received fast track and orphan drug designations from the FDA.

NLX-112 Shows Safety and Tolerability in Phase 2a Parkinson Trial, Supporting Further Development Louie Pasculli

A phase 2a trial showed that NLX-112 was safe and well tolerated in patients with Parkinson disease, while also reducing levodopa-induced dyskinesia and motor symptoms, supporting further clinical development.

NeuroVoices: Sneha Mantri, MD, MS, on Addressing Depression and Anxiety in Parkinson Care Marco Meglio

The chief medical officer at the Parkinson’s Foundation detailed how mood and behavioral symptoms shape quality of life in Parkinson disease and how clinicians can better identify and manage them.

Levacetylleucine Meets Primary and Secondary End Points in Phase 3 Ataxia-Telangiectasia Study Isabella Ciccone, MPH

IntraBio reported that levacetylleucine showed symptom improvement in the phase 3 IB1001-303 study for ataxia-telangiectasia, and it intends to proceed with regulatory submissions in multiple regions.

Migraine Medication Zavegepant Safe and Well Tolerated in Lactating Women, Phase 1 Study Shows Louie Pasculli

A Phase 1 study in healthy lactating women found that a single 10‑mg dose of zavegepant nasal spray was generally safe, well tolerated, and resulted in minimal infant exposure through breast milk.

FDA Requests HOPE-3 Clinical Study Report for Deramiocel BLA in DMD Cardiomyopathy Isabella Ciccone, MPH

The FDA requested the full data from the phase 3 HOPE-3 study as part of its review of the biologics license application for deramiocel, which Capricor plans to submit in February 2026.

Early Opicapone Initiation in Parkinson Leads to Continued Long-Term Therapeutic Benefits Marco Meglio

Early initiation of opicapone significantly reduces OFF time and enhances ON time in patients with recently diagnosed Parkinson's disease, improving overall treatment outcomes.

Low-Dose Opioids Show Long-Term Dose Stability, Effectiveness in Augmented Restless Legs Syndrome Louie Pasculli

A five-year analysis from the National RLS Opioid Registry found that most patients with dopamine agonist augmented restless legs syndrome maintained stable, low-dose opioid therapy with sustained symptom control.

Dopamine D3 Receptor Mesdopetam Maintains Antidyskinesia Effects Despite Failure to Improve Parkinson Disease ON Time Marco Meglio

A recent phase 2b study reveals mesdopetam's potential in reducing dyskinesia severity in Parkinson disease, despite no significant ON time improvement.

What the EC Decision on High-Dose Spinraza Means for SMA Care Marco Meglio, Stephanie Fradette, PhD

Stephanie Fradette, PharmD, head of neuromuscular development at Biogen, gave immediate reaction to the EC approval of high-dose nusinersen and its implications for evolving SMA treatment strategies.

Investigational COYA 302 Shows Feasibility, Preliminary Efficacy in Small Trial of Frontotemporal Dementia Marco Meglio

Coya Therapeutics reveals promising results for COYA 302, a potential treatment for frontotemporal dementia, showing cognitive stability and Treg enhancement.

This Week on NeurologyLive® — January 19, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

NeurologyLive® Brain Games: January 18, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the International Stroke Conference (ISC)!

NeurologyLive® Friday 5 — January 16, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 16, 2026.

Amantadine Immediate Release Lowers Dyskinesia Risk in Early Parkinson Disease, Study Shows Louie Pasculli

Use of immediate-release amantadine as an add-on to levodopa reduced peak-dose dyskinesia incidence in patients with early Parkinson disease, according to results from the phase 2 PREMANDYSK trial.

Recommended News For You

A garden can save your life

Early detection of breast cancer may be possible with AI-based mammography microcalcification detection and classification.

Journal Club: A well-accepted and safe method for soft tissue sarcoma biopsy.

Patients with resected head and neck cancers may benefit clinically from an investigational personalized vaccine.

Three-Drug Regimens Make Case for a Role in Untreated and Relapsed/Refractory CLL

"We Caught It Early": Advantage or Disadvantage?

Clinical trial: Patients with locally advanced, muscle-invasive bladder cancer do not benefit from extended lymph node removal.

Recommended Articles For You

Unleashing the Power of Immune Triads: A Novel Approach to Cancer Immunotherapy 

Advancements in Cancer Treatment and Survival Outcomes for Acute Myeloid Leukemia 

Uncovering the Causes of Thrombocytosis: A Journey to Improved Health 

Advancing Cancer Care: Insights into Oncology Trials, Immunotherapy, and CAR-T Innovations 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

More pain, more gain? New biopsy technique found to improve prostate cancer detection

2.

AI-based liquid biopsy shows promise for detecting brain cancer

3.

Researchers Challenge USPSTF's Lung Cancer Screening Criteria

4.

When Should Immunocompromised Individuals Receive a COVID Booster?

5.

Added Plinabulin Boosts OS as Later-Line Treatment for EGFR Wild-Type NSCLC

1.

Feline Anemia: Diagnosis and Treatment with Focus on Rasburicase Complications

2.

Revolutionizing Cancer Treatment: Advances in Immunotherapy and Cell Therapy

3.

Advancing Medical Oncology: Education, Certification, Clinical Trials, and Evolving Treatment Pathways

4.

CAR T + Ibrutinib in R/R Mantle Cell Lymphoma: Phase 2 TARMAC Study Insights

5.

Fresh Frozen Plasma: Its Role in Treating Trauma and Bleeding Disorders

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)

2.

Current Scenario of Cancer- Palliative Care to Close the Care Gap

3.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II

4.

Post Progression Approaches After First-line Third-Generaion ALK Inhibitors

5.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot